Cargando…
Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
BACKGROUND: Allergen immunotherapy using synthetic peptide T‐cell epitopes (Cat‐PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat‐allergic subjects. However, the immunological mechanisms unde...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817377/ https://www.ncbi.nlm.nih.gov/pubmed/31077596 http://dx.doi.org/10.1111/all.13867 |
_version_ | 1783463413602582528 |
---|---|
author | Rudulier, Christopher D. Tonti, Elena James, Eddie Kwok, William W. Larché, Mark |
author_facet | Rudulier, Christopher D. Tonti, Elena James, Eddie Kwok, William W. Larché, Mark |
author_sort | Rudulier, Christopher D. |
collection | PubMed |
description | BACKGROUND: Allergen immunotherapy using synthetic peptide T‐cell epitopes (Cat‐PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat‐allergic subjects. However, the immunological mechanisms underlying clinical benefit remain only partially understood. Since previous studies of whole allergen immunotherapy demonstrated a reduction in the frequency of allergen‐specific (MHC II tetramer(+)) CD4(+) T cells expressing the chemokine receptor CRTh2, we assessed the impact of Cat‐PAD on the frequency and functional phenotype of Fel d 1‐specific CD4(+) T cells. METHODS: Using before and after treatment samples from subjects enrolled in a randomized, double‐blind, placebo‐controlled trial of Cat‐PAD, we employed Fel d 1 MHC II tetramers and flow cytometry to analyze the expression of chemokine receptors CCR3, CCR4, CCR5, CXCR3, and CRTh2, together with markers of memory phenotype (CD27 and CCR7) on Fel d 1‐specific CD4(+) T cells. RESULTS: No statistically significant change in the frequency of Fel d 1‐specific CD4(+) T cells, nor in their expression of chemokine receptors or memory phenotype, was observed. However, a significant reduction in cell surface expression of CRTh2 was observed between the placebo and active groups (P = 0.047). CONCLUSIONS: Peptide immunotherapy with Cat‐PAD does not significantly alter the frequency or phenotype of Fel d 1‐CD4(+) T cells, but may decrease their expression of CRTh2. |
format | Online Article Text |
id | pubmed-6817377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68173772019-12-19 Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy Rudulier, Christopher D. Tonti, Elena James, Eddie Kwok, William W. Larché, Mark Allergy ORIGINAL ARTICLES BACKGROUND: Allergen immunotherapy using synthetic peptide T‐cell epitopes (Cat‐PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat‐allergic subjects. However, the immunological mechanisms underlying clinical benefit remain only partially understood. Since previous studies of whole allergen immunotherapy demonstrated a reduction in the frequency of allergen‐specific (MHC II tetramer(+)) CD4(+) T cells expressing the chemokine receptor CRTh2, we assessed the impact of Cat‐PAD on the frequency and functional phenotype of Fel d 1‐specific CD4(+) T cells. METHODS: Using before and after treatment samples from subjects enrolled in a randomized, double‐blind, placebo‐controlled trial of Cat‐PAD, we employed Fel d 1 MHC II tetramers and flow cytometry to analyze the expression of chemokine receptors CCR3, CCR4, CCR5, CXCR3, and CRTh2, together with markers of memory phenotype (CD27 and CCR7) on Fel d 1‐specific CD4(+) T cells. RESULTS: No statistically significant change in the frequency of Fel d 1‐specific CD4(+) T cells, nor in their expression of chemokine receptors or memory phenotype, was observed. However, a significant reduction in cell surface expression of CRTh2 was observed between the placebo and active groups (P = 0.047). CONCLUSIONS: Peptide immunotherapy with Cat‐PAD does not significantly alter the frequency or phenotype of Fel d 1‐CD4(+) T cells, but may decrease their expression of CRTh2. John Wiley and Sons Inc. 2019-06-07 2019-11 /pmc/articles/PMC6817377/ /pubmed/31077596 http://dx.doi.org/10.1111/all.13867 Text en © 2019 The Authors. Allergy Published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ORIGINAL ARTICLES Rudulier, Christopher D. Tonti, Elena James, Eddie Kwok, William W. Larché, Mark Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy |
title | Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy |
title_full | Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy |
title_fullStr | Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy |
title_full_unstemmed | Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy |
title_short | Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy |
title_sort | modulation of crth2 expression on allergen‐specific t cells following peptide immunotherapy |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817377/ https://www.ncbi.nlm.nih.gov/pubmed/31077596 http://dx.doi.org/10.1111/all.13867 |
work_keys_str_mv | AT rudulierchristopherd modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy AT tontielena modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy AT jameseddie modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy AT kwokwilliamw modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy AT larchemark modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy |